Predicting Success of Phase III Trials in Oncology
Stephan Hegge, Markus Thunecke, Matthias Krings, Léonard Ruedin, Jan Saputra Müller, Paul von Bünau
doi: https://doi.org/10.1101/2020.12.15.20248240
Stephan Hegge
1Hegge Holding UG, Kopernikusstr. 24, 10247 Berlin
PhDMarkus Thunecke
2Catenion GmbH, Münzstrasse 18, 10278 Berlin, Germany
PhDMatthias Krings
2Catenion GmbH, Münzstrasse 18, 10278 Berlin, Germany
PhDLéonard Ruedin
3idalab GmbH, Potsdamer Straße 68, 10785 Berlin, Germany
MScJan Saputra Müller
4AskBy GmbH, Boxhagener Str. 18, 10245 Berlin
MScPaul von Bünau
3idalab GmbH, Potsdamer Straße 68, 10785 Berlin, Germany
PhD
Posted December 16, 2020.
Predicting Success of Phase III Trials in Oncology
Stephan Hegge, Markus Thunecke, Matthias Krings, Léonard Ruedin, Jan Saputra Müller, Paul von Bünau
medRxiv 2020.12.15.20248240; doi: https://doi.org/10.1101/2020.12.15.20248240
Subject Area
Subject Areas
- Addiction Medicine (357)
- Allergy and Immunology (680)
- Anesthesia (182)
- Cardiovascular Medicine (2693)
- Dermatology (229)
- Emergency Medicine (405)
- Epidemiology (12330)
- Forensic Medicine (10)
- Gastroenterology (772)
- Genetic and Genomic Medicine (4166)
- Geriatric Medicine (392)
- Health Economics (689)
- Health Informatics (2703)
- Health Policy (1010)
- Hematology (366)
- HIV/AIDS (864)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3949)
- Nursing (214)
- Nutrition (587)
- Oncology (2083)
- Ophthalmology (596)
- Orthopedics (245)
- Otolaryngology (308)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (474)
- Pediatrics (1134)
- Primary Care Research (462)
- Public and Global Health (6591)
- Radiology and Imaging (1429)
- Respiratory Medicine (879)
- Rheumatology (415)
- Sports Medicine (345)
- Surgery (456)
- Toxicology (55)
- Transplantation (191)
- Urology (170)